Case Study
Alnylam Puts Sites and Patients First with IQVIA Technologies Investigator Site Portal
Six-year partnership plays pivotal role in rare disease trials
Mar 22, 2021

In rare disease research, every patient is precious. Read how the IQVIA Investigator Site Portal enables Alnylam Pharmaceutical’s patient-centered and site-first approach, which has delivered four approved products in the last two years and created an entirely new class of medications known as RNAi therapeutics.

Related solutions

Contact Us